Trial Profile
A Real-World Observational Study for the Safety and Efficacy of Baraclude (Entecavir) in Korean Pediatric (Aged 2-16 Years) Patients With Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jun 2019
Price :
$35
*
At a glance
- Drugs Entecavir (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 31 May 2019 Status changed from recruiting to completed.
- 21 Nov 2018 Planned number of patients changed from 20 to 6.
- 21 Nov 2018 Planned End Date changed from 28 Dec 2018 to 2 Dec 2019.